Vaxcyte, Inc. Common Stock (PCVX) Stock Price
PCVXStock
$63.62+45.95%52W
Market Cap$10.01B
P/E—
PEG Ratio—
Div yield—
Beta1.31
PCVX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-8.54%
Price vs S&P 500 (4W)9.30%
VGM Score74.91
PCVX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$2.10 | -$1.97 | +6.06%(+$0.13) | |
| Q1 2026 | -$1.77 | -$2.30 | -29.65%(-$0.53) | |
| Q4 2025 | -$1.50 | -$1.80 | -19.73%(-$0.30) | |
| Q3 2025 | -$1.24 | -$1.56 | -26.32%(-$0.32) | |
| Q2 2025 | -$1.16 | -$1.22 | -4.99%(-$0.06) |
PCVX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
PCVXVaxcyte, Inc. Common Stock | — | — | B | — | — | — | — | $63.62 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Vaxcyte, Inc. Common Stock
Vaxcyte is a clinical-stage biopharmaceutical company developing novel vaccines against bacterial infections, including pneumococcal disease, Group A Streptococcus, and Shigella. The company leverages its proprietary XpressCF cell-free protein synthesis platform to design advanced conjugate and protein vaccine candidates for both adult and pediatric populations. Its pipeline includes multiple vaccine programs at various development stages targeting significant public health needs.